Last €12.77 EUR
Change Today +0.20 / 1.59%
Volume 0.0
LMX On Other Exchanges
As of 9:32 AM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

luminex corp (LMX) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/26/13 - €17.90
52 Week Low
04/29/14 - €11.35
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for LUMINEX CORP (LMX)

Related News

No related news articles were found.

luminex corp (LMX) Related Businessweek News

No Related Businessweek News Found

luminex corp (LMX) Details

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the life sciences and diagnostic industries. It offers xMAP technology, an open architecture and multiplexing technology, which allows simultaneous analysis of approximately 500 bioassays from a drop of fluid by reading biological tests on the surface of microscopic polystyrene beads called microspheres; and MultiCode technology used for real-time polymerase chain reaction (PCR) and multiplexed PCR assays, as well as automation and robotics in the field of dry sample handling. The company operates in two segments: Technology and Strategic Partnerships (TSP); and Assays and Related Products (ARP). The TSP segment provides Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; and MAGPIX system, a versatile multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids. This segment also offers consumables comprising dyed polystyrene microspheres and sheath fluids. The ARP segment develops and sells assays on xMAP, xTAG, and MultiCode technology for use on its installed base of systems. It provides various assay products that consist of a combination of chemical and biological reagents; and company’s proprietary bead technology used to perform diagnostic and research assays on samples. This segment’s products are focused on the human genetics, personalized medicine, and infectious disease segments of the molecular diagnostic testing market. Luminex Corporation serves pharmaceutical companies, clinical laboratories, and research and medical institutions in the United States, Europe, Asia, Canada, Australia, and internationally. The company has collaboration with Merck & Co. Inc. to develop a companion diagnostic device. Luminex Corporation was founded in 1995 and is headquartered in Austin, Texas.

731 Employees
Last Reported Date: 02/26/14
Founded in 1995

luminex corp (LMX) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $700.0K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $360.5K
Senior Vice President of Operations
Total Annual Compensation: $332.8K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $320.9K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $319.2K
Compensation as of Fiscal Year 2013.

luminex corp (LMX) Key Developments

Laboratory Corporation of America(R) Holdings Announces the Availability of the xTAG(R) CYP2D6 Kit v3 from Luminex Corporation

Laboratory Corporation of America(R) Holdings announced the availability of the xTAG(R) CYP2D6 Kit v3 from Luminex Corporation. The xTAG CYP2D6 Kit v3 is an FDA cleared qualitative genotyping assay that aids clinicians in determining strategies for therapeutics metabolized by the CYP2D6 gene product. CYP2D6 is one of the genes in the cytochrome P450 family of enzymes that is responsible for metabolizing many drugs. Differences in cytochrome P450 activity can lead to adverse drug reactions or a lack of therapeutic effect from some drugs under standard therapy conditions. CYP2D6 is highly polymorphic, and 25% of all prescribed drugs are metabolized by the CPY2D6 enzyme. Genetic polymorphisms of CYP2D6 are associated with different drug metabolizing phenotypes and can be used to assess the potential for altered enzyme activity. Many commonly prescribed classes of drugs metabolized by CYP2D6 are used for treatment of cardiovascular conditions and clinical depression and as analgesics.

Luminex Corporation Announces Group B Streptococcus, as a Launch Menu Assay for its New Sample-to-Answer System, ARIES(TM)

Luminex Corporation announced that Group B Streptococcus (group B strep, GBS) is the fifth assay planned for the launch menu of its new sample-to-answer system, ARIES(TM). The assay will complement Luminex's growing portfolio of ASR and IVD products. Previously announced items in the five assay launch menu targeted for the ARIES system include: Flu A/B and RSV, HSV 1&2, Norovirus, and Clostridium difficile (C. diff). Infection with Group B Streptococcus is a cause of meningitis, pneumonia, and septicemia in newborns. GBS is a type of bacteria that can cause illness in people of all ages; however, it is the most common cause of some life-threatening infections in newborns. Women colonized with GBS during pregnancy are at increased risk of transmitting the bacteria to their newborn infant during labor and delivery. CDC's guidelines recommend that a pregnant woman be screened for group B strep when she is 35 to 37 weeks pregnant. ARIES GBS assay will deliver automated, sensitive results faster than culture methods, which can take several days for results and may require sub-culture to detect all strains. The ARIES GBS platform will deliver a streamlined workflow and generate rapid results with little hands-on time.

Luminex Corporation Presents at The 8th Annual SEMDA Conference, May-07-2014 08:45 AM

Luminex Corporation Presents at The 8th Annual SEMDA Conference, May-07-2014 08:45 AM. Venue: Waverly Hotel and Convention Center, Atlanta, Georgia, United States. Speakers: Patrick J. Balthrop, Chief Executive Officer, President, Director, Member of Executive Committee and Member of Strategy & Development Committee.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LMX:GR €12.77 EUR +0.20

LMX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Computer Programs & Systems Inc $64.82 USD +0.51
Fluidigm Corp $27.56 USD -0.23
HealthStream Inc $25.75 USD +3.50
Meridian Bioscience Inc $20.80 USD +0.29
Quidel Corp $22.49 USD +1.00
View Industry Companies

Industry Analysis


Industry Average

Valuation LMX Industry Range
Price/Earnings 46.8x
Price/Sales 3.3x
Price/Book 2.6x
Price/Cash Flow 37.3x
TEV/Sales 3.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LUMINEX CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at